Shares of NeuroMetrix, Inc. (NURO) are currently surging over 100% despite no stock related news.
NURO is currently trading at $4.56, up $2.41 or 112.093%, on the Nasdaq.
NeuroMetrix, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders.
The company has three FDA cleared commercial products. DPNCheck, a point-of-care test used to evaluate peripheral neuropathies, ADVANCE, a point-of-care device used as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies, and Quell 2.0, a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain that is available over-the-counter.
For comments and feedback contact: editorial@rttnews.com